MONMOUTH JUNCTION, N.J.,
July 18, 2011 /PRNewswire/ -- Insmed
Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today
announced that Andrea ("Andi") Holtzman
Drucker, J.D. has been appointed to the newly created
position of Senior Vice President, General Counsel and Corporate
Secretary, effective as of July 18,
2011. Ms. Drucker, who will report directly to
Timothy Whitten, President and Chief
Executive Officer of Insmed, will provide strategic legal and
business advice for various operational aspects of the Company.
Ms. Drucker brings more than 25 years of legal experience in the
biotechnology and pharmaceutical industries to Insmed. Most
recently, she served as Senior Vice President, General Counsel and
Secretary, for PuriCore plc, a publicly-traded biotechnology
company, where she advised the executive management and board of
directors on company legal matters. Prior to that, she spent
two years with Practical Business Solutions, a private legal
consulting firm, during which she served as Acting General Counsel
for Novavax, Inc., and as Interim Associate General Counsel for
Auxilium Pharmaceuticals, Inc., both publicly-traded biotechnology
companies, advising the companies on legal matters, including
licensing, research and development, intellectual property rights,
and FDA regulations. Ms. Drucker began her career at FMC
Corporation, a publicly-traded diversified chemicals company, where
she spent 17 years serving in a number of positions, including as
Group Counsel for the company's Specialty Chemicals Group, FMC
BioPolymer.
"Andi has a distinguished track record of providing strategic
legal counsel to growing companies, like Insmed," said Mr. Whitten.
"Her extensive experience with the regulatory and commercial
aspects of the pharmaceutical and biotechnology industries, as well
as the protection of intellectual property and SEC compliance
issues, make her an important addition to our management team."
"I am excited to be joining the Insmed management team, and look
forward to working with the Company as ARIKACE® (liposomal amikacin
for inhalation) continues to move forward on its development path
through to potential commercialization," said Ms. Drucker.
Ms. Drucker received her J.D. from the University of Pennsylvania Law School and a
Bachelors of Science with Distinction in Environmental Studies from
Cornell University.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on
the development of innovative inhaled pharmaceuticals for the
site-specific treatment of serious lung diseases. Insmed's
primary focus is on the development of inhaled antibiotic therapy
delivered via proprietary advanced pulmonary liposome technology in
areas of high unmet need in lung diseases. For more
information, please visit http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Investors are cautioned that such statements in this
release, including statements relating to our financial positions,
results of operations, the results of clinical trials and clinical
data described herein, the development of our products, and the
business strategies, plans and objectives of management, constitute
forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those
anticipated by the forward-looking statements. Our results
may be affected by such factors as the receipt and timing of FDA
and other regulatory approvals, if at all, competitive developments
affecting our product development, delays in product development or
clinical trials, and patent disputes involving currently developing
products. The risks and uncertainties include, without
limitation, our future clinical trials may not support the data
described in this release, we may be unsuccessful in developing our
product candidates or receiving necessary regulatory approvals, we
may experience delays in our product development or clinical
trials, our product candidates may not prove to be commercially
successful, our expenses may be higher than anticipated and other
risks and challenges detailed in our filings with the U.S.
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the year ended December 31,
2010. Investors are cautioned not to place undue
reliance on any forward-looking statements which speak only as of
the date of this release. We undertake no obligation to
publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.
Investor Relations Contact:
Brian Ritchie - FD
212-850-5683
brian.ritchie@fd.com
Media Contact:
Irma Gomez-Dib - FD
212-850-5761
irma.gomez-dib@fd.com
SOURCE Insmed Incorporated